Citron Research exposes Exact Sciences and PROVES beyond ANY doubt why this stock will soon be cut in half

, , ,

Every Man and Woman Over The Age of 50 MUST read this report from Citron Research

Short term target:  $20.

3 to 5 Years:  Likely Single Digit, Potential 0.

Exact Sciences (NASDAQ:EXAS) pushes a cancer test (Cologuard) to the public, inferior by its own admission, and loses money doing it.  That is why this $4 billion company is mainly owned by passive investing ETFs or other healthcare baskets.

More importantly, as Citron will expose, the key metrics not disclosed by Exact Sciences are getting worse, while Medicare pricing inefficiencies end next January and investors will be left with a decaying asset with no terminal value.

This stock is a poster child for what goes wrong when Wall Street gets ahold of a health care concept with no discrimination for whether its good or bad medicine.

For the rest of the story you won’t read anywhere else, click here: 


Citron Exposes the Dirty Illegal Secrets of FleetCor, and Proof the Company is Already in Cover-Up Mode

, ,

Short Term Price Target = $80

In our first report Citron referred to FleetCor (NYSE:FLT) as “FeeCor” and “FleeceCor”.  The bulls defended the company, claiming FleetCor’s customer fees are legal, not egregious, and most of all are sustainable.

In this report Citron clarifies the illegality of FleetCor’s corporate practices, and the lengths the analyst community goes to in defending them.

For the rest of the story you won’t read anywhere else, Click Here…

FleetCor — Or is it FeeCor or FleeceCor?

, ,

As the truth about FleetCor (NYSE:FLT) becomes more apparent to regulators and its customers, the stock should hit a short-term price target of $100.

Citron analyzes a company who has become so insanely financially dependent on fleecing its own customers, that its financials are seriously imperiled and its valuation is totally out of touch with reality.

For the rest of the story that you won’t see anywhere else, Click Here …


Citron Exposes More Undisclosed Relationships at TransDigm

, ,

What the Company and Its Analysts Call “A Game”
Is Actually Illegal

Price Target $140

Citron predicts that after this report makes its rounds, TransDigm’s (NYSE:TDG) days of exploiting and deceiving the Federal Government are numbered.

Valeant Pharmaceuticals has recently hit prices that some never thought imaginable. As Citron observes today, at $12 per share, that stock is down over 95% from its highs just months prior to Citron’s reporting on Philidor. The questions then turn to:

“How did so many ‘smart’ people get it so wrong?”


“When could this possibly happen again?”

 For the Rest of the Story you Won’t Read Anywhere Else, Click Here … 

Citron Exposes the Vulnerability of Motorola Solutions — Price Target $45

, ,

What would President Trump think ?
U.S. Law Enforcement Agencies Paying 5 TIMES the Prices
Motorola Charges EU Countries?

How Motorola Really Makes Its Money!

 While Motorola’s has many operating divisions, the bulk of its profits come from selling overpriced handsets into its single source contracts in the United States….taking advantage of both tax payers and the first responder community.  In fact, handset sales in the U.S. carry an 83.6% gross margin (see below), while device sales in Europe are at 9%.

Citron’s analysis shows that U.S. device (handset) sales are contributing a whopping 76.7% of Motorola’s bottom line!

As new technologies eclipse Motorola’s monopoly grip on its outdated U.S. first responder’s network, the company’s gravy train of egregious handset pricing will fall to competition.  In the current political environment, how long can Motorola’s “extreme lobbying” efforts protect it from competitive pressures?

Citron exposes the secret of the Motorola cash cow — gouging the U.S. Government.  

For the rest of the story you won’t read anywhere else, Click Here: